Q1 Earnings Estimate for AUTL Issued By William Blair

Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for shares of Autolus Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics' Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.18) EPS.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.12. The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $2.98 million.

Other equities analysts also recently issued reports about the stock. Truist Financial decreased their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Finally, Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $1.40 on Friday. The stock has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $2.49. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $5.00. The company has a market cap of $372.53 million, a price-to-earnings ratio of -1.16 and a beta of 2.06.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $26,000. Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after acquiring an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the 4th quarter worth $35,000. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth $47,000. Finally, Daiwa Securities Group Inc. boosted its position in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after acquiring an additional 8,479 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.